Ovarian cancer drugs are used to treat cancers that begin in the ovaries. Some of the common ovarian cancer drugs include carboplatin, paclitaxel, and doxorubicin. The drugs help reduce tumor size and kill cancer cells. With rising cases of ovarian cancer worldwide, the demand for effective drugs to treat the disease is growing.
The global Ovarian Cancer Drugs Market is estimated to be valued at US$6.2 billion in 2030 and is expected to exhibit a CAGR of 6.6% over the forecast period of 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Increasing prevalence of ovarian cancer is a key trend fueling the growth of the ovarian cancer drugs market. As per statistics by Cancer Research UK, around 7,400 new cases of ovarian cancer are diagnosed annually in the UK alone. Similarly, American Cancer Society estimates around 21,410 new cases and 13,770 deaths from ovarian cancer in the United States each year. The rising incidence of ovarian cancer can be attributed to various factors such as family history, fertility drugs, and genetic mutations. With growing prevalence, the demand for effective ovarian cancer drugs for treatment is expected to surge over the forecast period.
SWOT Analysis
Strength: Ovarian cancer drugs market has seen the entry of several targeted therapies and immunotherapy drugs which has improved survival rates.
Weakness: High cost of targeted therapies and lack of awareness about early symptoms of ovarian cancer limiting market growth.
Opportunity: Increasing research funding and collaborations between pharma companies and research institutes working on development of therapies targeting hard-to-treat cancers.
Threats: Expiry of patents of blockbuster drugs to increase competition and development of resistant cancer strains poses challenges.
Key Takeaways
The global ovarian cancer drugs market is expected to witness high growth. The global Ovarian Cancer Drugs Market is estimated to be valued at US$6.2 billion in 2030 and is expected to exhibit a CAGR of 6.6% over the forecast period of 2023 to 2030.
Regional analysis related content comprises the North American region currently dominates the market due to established healthcare infrastructure and increasing adoption of premium-priced drug therapies.
Key players related content comprises Key players operating in the ovarian cancer drugs market are Roche, AstraZeneca, Clovis Oncology, Boehringer Ingelheim GmbH, Pfizer Inc., Synta Pharmaceuticals Corp., Cellceutix Corporation, and Bristol-Myers Squibb Company.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
